Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study

Summary

NIMBLE is a prospective study for blood biomarker study of lung nodules alongside analysing data which has been collected routinely as part of patient care. The primary aim of NIMBLE is to assess whether artificial intelligence and machine learning based radiomics approaches can be used to distinguish between benign disease and malignancy in a new lung nodule after a previously treated cancer, and where malignant to differentiate between metastatic recurrence or a new primary lung cancer.

Eligibility

Inclusion Criteria:

* Patients under active investigation or surveillance for incidental lung nodules
* Age \> 18.

Exclusion Criteria:

* Active or previous diagnosis of malignancy (within 5 years preceding baseline scan).
* Inability to give informed consent.
* Active infection (including tuberculosis or fungal infection).
* Clinician-suspected or confirmed active or recent COVID-19 infection (less than 4 weeks before CT scan or required blood sampling date).

Conditions2

Browse More Trials